Restructure Information

On September 15, 2019, Purdue Pharma L.P. announced a preliminary agreement to settle the opioid litigation facing the Company.

We’re working toward a settlement that would deliver more than $10 billion in value and address the opioid crisis by, among other things, providing needed funds, as well as millions of doses of lifesaving opioid addiction treatment and overdose reversal medicines.

The settlement is designed to speed the delivery of resources and vital medicines that communities can use to address and abate the opioid crisis.

Purdue is working to garner additional support for the settlement and seeks to implement a final resolution through the federal bankruptcy system.  We are working to emerge from bankruptcy as a public benefit company with a focus on addressing the opioid crisis and established for the benefit of claimants and the American people.